155 related articles for article (PubMed ID: 26062569)
1. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
2. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
Fujiwara N; Kawasaki H; Yabe R; Christensen DJ; Vitek MP; Mizuno T; Sato K; Ohama T
J Vet Med Sci; 2013; 75(3):349-54. PubMed ID: 23131782
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
4. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
7. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
[TBL] [Abstract][Full Text] [Related]
8. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
10. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
11. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
[TBL] [Abstract][Full Text] [Related]
12. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of an anti-cancer strategy targeting SET in canine osteosarcoma.
Tsuji S; Ohama T; Nakagawa T; Sato K
J Vet Med Sci; 2019 Oct; 81(10):1424-1430. PubMed ID: 31527340
[TBL] [Abstract][Full Text] [Related]
14. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
Fujiki H; Sueoka E; Watanabe T; Suganuma M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
[TBL] [Abstract][Full Text] [Related]
15. The role of SET/I2PP2A in canine mammary tumors.
Kake S; Tsuji S; Enjoji S; Hanasaki S; Hayase H; Yabe R; Tanaka Y; Nakagawa T; Liu HP; Chang SC; Usui T; Ohama T; Sato K
Sci Rep; 2017 Jun; 7(1):4279. PubMed ID: 28655918
[TBL] [Abstract][Full Text] [Related]
16. Ceramide in the prostate.
Dent P
Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
[TBL] [Abstract][Full Text] [Related]
17. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
18. Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating MEK1/2-ERK1/2 signaling in canine melanoma cells.
Yamamoto M; Fujiwara N
J Vet Med Sci; 2023 Sep; 85(9):977-984. PubMed ID: 37495516
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of perphenazine on canine lymphoma.
Tsuji S; Yabe R; Usui T; Mizuno T; Ohama T; Sato K
J Vet Med Sci; 2016 Sep; 78(8):1293-8. PubMed ID: 27150024
[TBL] [Abstract][Full Text] [Related]
20. 6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.
Chon E; Flanagan B; de Sá Rodrigues LC; Piskun C; Stein TJ
Vet J; 2015 Aug; 205(2):305-12. PubMed ID: 25130776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]